Skip to main content
. 2010 Oct 1;4:95–105. doi: 10.4137/CMO.S4088

Figure 1.

Figure 1.

Evidence-based treatment algorithm for treatment-naïve metastatic renal cell carcinoma (category 1).

Note: *Temsirolimus is FDA approved for the first line treatment of poor risk or non clear cell histology metastatic renal cell carcinoma (category 1).42